T-cell Lymphoma Market Size, Share & Trends Analysis Report By Lymphoma Type (Peripheral T-cell Lymphoma, T-cell Lymphoblastic Lymphoma), By Therapy, By Region, And By Segment Forecasts, 2025-2034

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global T-cell Lymphoma Market Snapshot Chapter 4. Global T-cell Lymphoma Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Porter's Five Forces Analysis 4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031 4.8. Global T-cell Lymphoma Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031 4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023) 4.10. Use/impact of AI on T-cell Lymphoma Market Industry Trends Chapter 5. T-cell Lymphoma Market Segmentation 1: By Therapy, Estimates & Trend Analysis 5.1. Market Share by Therapy, 2023 & 2031 5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Therapy: 5.2.1. Radiotherapy 5.2.2. Chemotherapy 5.2.3. Immunotherapy 5.2.4. Stem Cell Transplantation 5.2.5. Others (Antiviral Therapy, etc.) Chapter 6. T-cell Lymphoma Market Segmentation 2: By Lymphoma Type, Estimates & Trend Analysis 6.1. Market Share by Lymphoma Type, 2023 & 2031 6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Lymphoma Type: 6.2.1. Peripheral T-cell Lymphoma 6.2.1.1. Cutaneous T-cell Lymphoma 6.2.1.2. Anaplastic Large Cell Lymphoma 6.2.1.3. Angio-immuno-blastic T-cell Lymphoma 6.2.1.4. Others 6.2.1.4.1. Intestinal T-cell Lymphoma 6.2.1.4.2. Follicular T-cell lymphoma 6.2.2. T-cell Lymphoblastic Lymphoma Chapter 7. T-cell Lymphoma Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. Global T-cell Lymphoma Market , Regional Snapshot 2023 & 2031 7.2. North America 7.2.1. North America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 7.2.1.1. US 7.2.1.2. Canada 7.2.2. North America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031 7.2.3. North America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Lymphoma Type, 2024-2031 7.3. Europe 7.3.1. Europe T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 7.3.1.1. Germany 7.3.1.2. U.K. 7.3.1.3. France 7.3.1.4. Italy 7.3.1.5. Spain 7.3.1.6. Rest of Europe 7.3.2. Europe T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031 7.3.3. Europe T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Lymphoma Type, 2024-2031 7.4. Asia Pacific 7.4.1. Asia Pacific T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 7.4.1.1. India 7.4.1.2. China 7.4.1.3. Japan 7.4.1.4. Australia 7.4.1.5. South Korea 7.4.1.6. Hong Kong 7.4.1.7. Southeast Asia 7.4.1.8. Rest of Asia Pacific 7.4.2. Asia Pacific T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031 7.4.3. Asia Pacific T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts By Lymphoma Type, 2024-2031 7.5. Latin America 7.5.1. Latin America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031 7.5.1.1. Brazil 7.5.1.2. Mexico 7.5.1.3. Rest of Latin America 7.5.2. Latin America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031 7.5.3. Latin America T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Lymphoma Type, 2024-2031 7.6. Middle East & Africa 7.6.1. Middle East & Africa T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031 7.6.1.1. GCC Countries 7.6.1.2. Israel 7.6.1.3. South Africa 7.6.1.4. Rest of Middle East and Africa 7.6.2. Middle East & Africa T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Therapy, 2024-2031 7.6.3. Middle East & Africa T-cell Lymphoma Market Revenue (US$ Million) Estimates and Forecasts by Lymphoma Type, 2024-2031 Chapter 8. Competitive Landscape 8.1. Major Mergers and Acquisitions/Strategic Alliances 8.2. Company Profiles 8.2.1. 4SC AG 8.2.1.1. Business Overview 8.2.1.2. Key Product/Service Overview 8.2.1.3. Financial Performance 8.2.1.4. Geographical Presence 8.2.1.5. Recent Developments with Business Strategy 8.2.2. Acrotech Biopharma 8.2.3. Affimed 8.2.4. Bausch Health Companies Inc. 8.2.5. Biocryst Pharmaceuticals Inc. 8.2.6. Bristol-Myers Squibb Company 8.2.7. Chipscreen Biosciences 8.2.8. Citius Pharma 8.2.9. CSPC 8.2.10. CStone Pharmaceuticals 8.2.11. Daiichi-Sankyo 8.2.12. Dizal Pharma 8.2.13. Eisai 8.2.14. Elorac 8.2.15. Hoffmann-La Roche Ltd 8.2.16. Genmab A/S 8.2.17. Genor Biopharma 8.2.18. GlaxoSmithKline plc. 8.2.19. Innate Pharma 8.2.20. Johnson and Johnson Private Limited 8.2.21. Kyowa Kirin Co., Ltd. 8.2.22. Merck and Co. Inc. 8.2.23. Novartis AG 8.2.24. Pfizer 8.2.25. Roche 8.2.26. Seagen Inc. 8.2.27. Secura Bio 8.2.28. Shanghai Junshi Bio 8.2.29. SHIONOGI & Co., Ltd. 8.2.30. Solasia 8.2.31. Spectrum Pharmaceuticals Inc. 8.2.32. Takeda 8.2.33. Viracta 8.2.34. Other Prominent Players